Articles

Characterization of breakthrough hemolysis events observed in the phase 3 randomized studies of ravulizumab versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria

Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA;
Université Paris Diderot and Hôpital Saint-Louis AP-HP, Paris, France;
Alexion Pharmaceuticals, Inc., Boston, MA, USA;
Department of Hematology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany;
Department of Clinical Medicine and Surgery, Federico II University of Naples, Naples, Italy;
Jane Anne Nohl Division of Hematology, Keck-USC School of Medicine, Los Angeles, CA, USA;
Department of Haematology, St James's University Hospital, Leeds, UK;
Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH, USA;
Clinical Haematology, Royal Melbourne Hospital, Melbourne, Australia;
The Catholic University of Korea, College of Medicine, Seoul, Republic of Korea;
Department of Haematological Medicine, King College Hospital, London, UK;
Alexion Pharmaceuticals, Inc., Boston, MA, USA;
Alexion Pharmaceuticals, Inc., Boston, MA, USA;
Alexion Pharmaceuticals, Inc., Boston, MA, USA;
Alexion Pharmaceuticals, Inc., Boston, MA, USA;
Alexion Pharmaceuticals, Inc., Boston, MA, USA;
Department of Haematology, St James's University Hospital, Leeds, UK;
German Red Cross Blood Transfusion Service Baden-Wurttemberg-Hessen and University Hospital Ulm
Haematologica Early view Jan 16, 2020 https://doi.org/10.3324/haematol.2019.236877